

CCM2 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6875a**Specification**

CCM2 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q9BSQ5](#)**CCM2 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 83605**Other Names**

Malcavernin, Cerebral cavernous malformations 2 protein, CCM2, C7orf22

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6875a](/products/AP6875a) was selected from the N-term region of human CCM2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CCM2 Antibody (N-term) Blocking Peptide - Protein Information**Name** CCM2**Synonyms** C7orf22**Function**

Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity. May act through the stabilization of endothelial cell junctions (By similarity). May function as a scaffold protein for MAP2K3-MAP3K3 signaling. Seems to play a major role in the modulation of MAP3K3-dependent p38 activation induced by hyperosmotic shock (By similarity).

Cellular Location

Cytoplasm.

CCM2 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CCM2 Antibody (N-term) Blocking Peptide - Images

CCM2 Antibody (N-term) Blocking Peptide - Background

CCM2 is a scaffold protein that functions in the stress-activated p38 Mitogen-activated protein kinase (MAPK) signaling cascade. The protein interacts with SMAD specific E3 ubiquitin protein ligase 1 (also known as SMURF1) via a phosphotyrosine binding domain to promote RhoA degradation. The protein is required for normal cytoskeletal structure, cell-cell interactions, and lumen formation in endothelial cells.

CCM2 Antibody (N-term) Blocking Peptide - References

Penco,S., et.al., J. Neurosurg. 110 (5), 929-934 (2009)